Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
UBS
Citi
Deloitte
AstraZeneca
Accenture
Chinese Patent Office
Fuji
Johnson and Johnson

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TAPENTADOL HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Tapentadol Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00361504 A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain Completed Grünenthal GmbH Phase 3 The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients with at least a 3-month history of low back pain, or pain caused by knee or hip osteoarthritis.
NCT00361504 A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients with at least a 3-month history of low back pain, or pain caused by knee or hip osteoarthritis.
NCT00361582 A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery Completed Grünenthal GmbH Phase 3 The purpose of this study is to evaluate in patients who are eligible for elective primary total or partial joint replacement of the hip or knee due to chronic osteoarthritis the efficacy (level of pain control) of CG5503 over 5 and 10 days compared with placebo, and to assess the safety and tolerability of multiple doses of CG5503 IR patients.
NCT00361582 A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 The purpose of this study is to evaluate in patients who are eligible for elective primary total or partial joint replacement of the hip or knee due to chronic osteoarthritis the efficacy (level of pain control) of CG5503 over 5 and 10 days compared with placebo, and to assess the safety and tolerability of multiple doses of CG5503 IR patients.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Tapentadol Hydrochloride

Condition Name

Condition Name for Tapentadol Hydrochloride
Intervention Trials
Pain 18
Low Back Pain 11
Osteoarthritis 6
Chronic Pain 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tapentadol Hydrochloride
Intervention Trials
Back Pain 14
Osteoarthritis 13
Low Back Pain 13
Chronic Pain 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tapentadol Hydrochloride

Trials by Country

Trials by Country for Tapentadol Hydrochloride
Location Trials
United States 209
Canada 22
Spain 13
Germany 13
Poland 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tapentadol Hydrochloride
Location Trials
North Carolina 11
New York 11
Florida 10
Utah 9
Texas 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tapentadol Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Tapentadol Hydrochloride
Clinical Trial Phase Trials
Phase 4 9
Phase 3 32
Phase 2/Phase 3 1
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tapentadol Hydrochloride
Clinical Trial Phase Trials
Completed 45
Terminated 9
Recruiting 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tapentadol Hydrochloride

Sponsor Name

Sponsor Name for Tapentadol Hydrochloride
Sponsor Trials
Grünenthal GmbH 39
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 28
Janssen Pharmaceutical K.K. 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tapentadol Hydrochloride
Sponsor Trials
Industry 84
Other 10
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Queensland Health
Merck
Argus Health
Medtronic
Julphar
Mallinckrodt
AstraZeneca
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.